Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study.
暂无分享,去创建一个
B. Littenberg | H. Muss | L. Demers | M. Wood | Charles D MacLean | S. Mount | Julia G. Johnson | S. Witherby
[1] C. Labrie,et al. High internal consistency and efficacy of intravaginal DHEA for vaginal atrophy , 2010, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.
[2] P. Dubey,et al. A comparative study of the effects of local estrogen with or without local testosterone on vulvovaginal and sexual dysfunction in postmenopausal women. , 2010, The journal of sexual medicine.
[3] M. Moasser,et al. A Phase II Study of Vaginal Testosterone Cream (TEST) vs. Estring for Vaginal Dryness or Decreased Libido in Women with Early Stage Breast Cancer (BC) Treated with Aromatase Inhibitors (AIs). , 2009 .
[4] C. Labrie,et al. Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration , 2009, Menopause.
[5] C. Labrie,et al. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women , 2009, Menopause.
[6] C. Labrie,et al. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy , 2009, Menopause.
[7] R. Wolfe,et al. The incidence of invasive breast cancer among women prescribed testosterone for low libido. , 2009, The journal of sexual medicine.
[8] F. Berrino,et al. Sex Hormone Levels, Breast Cancer Risk, and Cancer Receptor Status in Postmenopausal Women: the ORDET Cohort , 2009, Cancer Epidemiology Biomarkers & Prevention.
[9] G. Braunstein,et al. Testosterone and the breast , 2008, Menopause international.
[10] C. Rock,et al. Reproductive Steroid Hormones and Recurrence-Free Survival in Women with a History of Breast Cancer , 2008, Cancer Epidemiology Biomarkers & Prevention.
[11] Graham A Colditz,et al. Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women. , 2006, Journal of the National Cancer Institute.
[12] D. Spiegelman,et al. Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. , 2006, Journal of the National Cancer Institute.
[13] M. Dowsett,et al. Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] H. Burger. Faculty Opinions recommendation of Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. , 2006 .
[15] T. Marshall,et al. Menopausal symptoms in women treated for breast cancer: the prevalence and severity of symptoms and their perceived effects on quality of life , 2006, Climacteric : the journal of the International Menopause Society.
[16] C. Castelo-Branco,et al. Management of post-menopausal vaginal atrophy and atrophic vaginitis. , 2005, Maturitas.
[17] G. Braunstein,et al. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. , 2005, The Journal of clinical endocrinology and metabolism.
[18] N. Watts,et al. Safety and Efficacy of a Testosterone Patch for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women: A Randomized, Placebo-Controlled Trial , 2005 .
[19] F. Berrino,et al. Serum testosterone levels and breast cancer recurrence , 2005, International journal of cancer.
[20] J. Cuzick,et al. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] E. van Limbergen,et al. Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients , 2004, Anti-cancer drugs.
[22] S. Davis,et al. Testosterone effects on the breast: implications for testosterone therapy for women. , 2004, Endocrine reviews.
[23] L. Speroff. Efficacy and tolerability of a novel estradiol vaginal ring for relief of menopausal symptoms. , 2003, Obstetrics and gynecology.
[24] Mitch Dowsett,et al. Aromatase inhibitors in breast cancer. , 2003, The New England journal of medicine.
[25] G. Davila,et al. Are women with urogenital atrophy symptomatic? , 2003, American journal of obstetrics and gynecology.
[26] R. Santen. To block estrogen's synthesis or action: that is the question. , 2002, The Journal of clinical endocrinology and metabolism.
[27] J. A. van der Laak,et al. The effect of Replens on vaginal cytology in the treatment of postmenopausal atrophy: cytomorphology versus computerised cytometry. , 2002, Journal of clinical pathology.
[28] Orman,et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. , 2000, The New England journal of medicine.
[29] J. Manson,et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. , 1998, Journal of the National Cancer Institute.
[30] B. Pasternack,et al. Relation of serum levels of testosterone and dehydroepiandrosterone sulfate to risk of breast cancer in postmenopausal women. , 1997, American journal of epidemiology.
[31] A. Straughn,et al. Delivery of dehydroepiandrosterone to premenopausal women: effects of micronization and nonoral administration. , 1996, American journal of obstetrics and gynecology.
[32] M. Notelovitz. Estrogen therapy in the management of problems associated with urogenital ageing: a simple diagnostic test and the effect of the route of hormone administration. , 1995, Maturitas.
[33] M. Dowsett,et al. ARIMIDEX™: A new oral, once-a-day aromatase inhibitor , 1995, The Journal of Steroid Biochemistry and Molecular Biology.
[34] R. Santen,et al. Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer , 1995, Cancer.
[35] M. Gelfand,et al. Treating Vaginal Dryness in Breast Cancer Patients: Results of Applying a Polycarbophil Moisturizing Gel , 1994 .
[36] E. Nieschlag,et al. TRANSDERMAL TESTOSTERONE , 1989, The Lancet.
[37] E. McFadden,et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.
[38] J. Hustin,et al. Cytologic evaluation of the effect of various estrogens given in postmenopause. , 1977, Acta cytologica.
[39] S. Salinger. Proliferative effect of testosterone propionate on human vaginal epithelium. , 1950, Acta endocrinologica.
[40] F. Wilcoxon. Individual Comparisons by Ranking Methods , 1945 .
[41] W. Steinberg,et al. 17&bgr;‐Estradiol Vaginal Tablet Versus Conjugated Equine Estrogen Vaginal Cream to Relieve Menopausal Atrophic Vaginitis , 2000 .
[42] A. Dobs,et al. Transdermal testosterone. Viewpoints , 1998 .
[43] B. Risberg,et al. The vaginal epithelium in the postmenopause--cytology, histology and pH as methods of assessment. , 1995, Maturitas.
[44] L. Nachtigall. Comparative study: Replens versus local estrogen in menopausal women. , 1994, Fertility and sterility.
[45] H. Adlercreutz,et al. Inhibition of aromatase with CGS 16949A in postmenopausal women. , 1989, The Journal of clinical endocrinology and metabolism.